Systematic Reviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Aug 26, 2024; 16(8): 469-483
Published online Aug 26, 2024. doi: 10.4330/wjc.v16.i8.469
Tissue-source effect on mesenchymal stem cells as living biodrugs for heart failure: Systematic review and meta-analysis
Moaz Safwan, Mariam Safwan Bourgleh, Mohamed Aldoush, Khawaja Husnain Haider
Moaz Safwan, Mariam Safwan Bourgleh, Mohamed Aldoush, Khawaja Husnain Haider, Department of Basic Sciences, Sulaiman Al Rajhi University, Al Bukairiyah 51941, Saudi Arabia
Author contributions: Haider KH designed and produced the study and its methodology; Safwan M and Bourgleh MS performed database research and screened the extracted records against eligibility criteria; Bourgleh MS, Aldoush M, and Safwan M performed the data extraction and plotting; Safwan M and Aldoush M reviewed and validated the extracted data; Safwan M and Bourgleh MS performed the quality assessment of the included trials; Bourgleh MS and Safwan M conducted the statistical analysis; Safwan M and Haider KH drafted the first manuscript; All the authors contributed to the final manuscript, reviewed the final manuscript and have read and agreed to the published version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Khawaja Husnain Haider, PhD, Professor, Department of Basic Sciences, Sulaiman Al Rajhi University, PO Box 777, Al Bukairiyah 51941, Saudi Arabia. kh.haider@sr.edu.sa
Received: May 6, 2024
Revised: June 24, 2024
Accepted: July 23, 2024
Published online: August 26, 2024
Processing time: 112 Days and 3.2 Hours
Core Tip

Core Tip: Mesenchymal stem cells (MSCs) are fast emerging as living biodrugs to repair and replace dysfunctional myocardium. While MSCs are available from diverse adult and fetal tissues, bone-marrow-derived MSCs (BM-MSCs; adult tissue source) and umbilical-cord-derived MSCs (UC-MSCs; fetal tissue source) remain the most well-studied types during recent clinical trials. The primary aim of this systematic review and meta-analysis was to evaluate the comparative safety and effectiveness of BM-MSC- and UC-MSC-based therapy in heart failure patients, analyzing left ventricular ejection fraction and 6-min walking distance as the primary functional and clinical outcomes.